20.927 articles found

Depression treatment in Parkinson's disease.

Driver PS.

DICP · 1991-02-01

PMID: 2058186

Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?

Russ H, Mihatsch W, Gerlach M, Riederer P, Przuntek H.

Neurosci Lett · 1991-02-01

DOI: 10.1016/0304-3940(91)90171-oPMID: 1712088

Adjuvant therapy in Parkinson's disease

Critchley PHS.

· 1991-01-01

Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP.

Taylor MD, de Ceballos ML, Rose S, Chong PN, Jenner P, Marsden CD.

J Neural Transm Park Dis Dement Sect · 1991-01-01

DOI: 10.1007/bf02260885PMID: 1716907

Electroconvulsive therapy in untreated Parkinson's disease.

Stern MB.

Mov Disord · 1991-01-01

DOI: 10.1002/mds.870060314PMID: 1922134

(-)-Deprenyl treatment of patients with Parkinson's disease does not affect erythrocyte catechol-O-methyl transferase activity.

Russ H, Gerlach M, Dettner O, Kuhn W, Przuntek H.

J Neural Transm Park Dis Dement Sect · 1991-01-01

DOI: 10.1007/bf02259539PMID: 1958292

Side effects during long-term treatment with depot antipsychotic medication.

Cookson JC.

Clin Neuropharmacol · 1991-01-01

PMID: 1751940

Effects of treatment with trihexyphenidyl on cognitive function in early Parkinson's disease.

Schelosky L, Benke T, Poewe WH.

J Neural Transm Suppl · 1991-01-01

DOI: 10.1007/978-3-7091-9135-4_20PMID: 1753241

Striatal neurons express increased level of dopamine D2 receptor mRNA in response to haloperidol treatment: a quantitative in situ hybridization study.

Bernard V, Le Moine C, Bloch B.

Neuroscience · 1991-01-01

DOI: 10.1016/0306-4522(91)90108-zPMID: 1754061

Substantia nigra grafts and Parkinson's disease: from animal experiments to human therapeutic trials.

Freed WJ.

Restor Neurol Neurosci · 1991-01-01

DOI: 10.3233/rnn-1991-3301PMID: 21551873

Electroconvulsive therapy in Parkinson's disease and other movement disorders.

Faber R, Trimble MR.

Mov Disord · 1991-01-01

DOI: 10.1002/mds.870060405PMID: 1758447

Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa.

Deleu D, Ebinger G, Michotte Y.

Eur J Clin Pharmacol · 1991-01-01

DOI: 10.1007/bf00626368PMID: 1761073